BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 Outubro 2023 - 8:30AM
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the
“Company”), a commercial-stage biopharmaceutical company focused on
genetic diseases and cancers, today announced that on October 06,
2023, the compensation committee of BridgeBio’s board of directors
granted nineteen new employees restricted stock units for an
aggregate of 227,507 shares of the Company’s common stock. With
respect to 120,975 shares of restricted stock units, one-fourth of
the shares underlying the restricted stock units will vest on
November 16, 2024, with one-twelfth of the remaining shares
underlying restricted stock units vesting on a quarterly basis
thereafter. With respect to 106,532 shares of restricted stock
units, one-eighth of the shares underlying the restricted stock
units will vest on February 16, 2024, with one-fourteenth of the
remaining shares underlying the restricted stock units vesting on a
quarterly basis thereafter. In each case, the vesting is subject to
each such employee’s continued employment with the Company or one
of its subsidiaries on such vesting dates. All of the
above-described awards were made under BridgeBio’s Amended and
Restated 2019 Inducement Equity Plan (the “Plan”).
The above-described awards were each granted as an inducement
material to the employees entering into employment with the Company
in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted
pursuant to the terms of the Plan. The Plan was adopted by
BridgeBio’s board of directors in November 2019 and amended and
restated on February 10, 2023.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical
company founded to discover, create, test, and deliver
transformative medicines to treat patients who suffer from genetic
diseases and cancers with clear genetic drivers. BridgeBio’s
pipeline of development programs ranges from early science to
advanced clinical trials. BridgeBio was founded in 2015 and its
team of experienced drug discoverers, developers and innovators are
committed to applying advances in genetic medicine to help patients
as quickly as possible. For more information
visit bridgebio.com and follow us
on LinkedIn and Twitter.
BridgeBio Contact:
Vikram Balicontact@bridgebio.com(650)-789-8220
BridgeBio Pharma (NASDAQ:BBIO)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
BridgeBio Pharma (NASDAQ:BBIO)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024